If you have retinal vein occlusion (RVO) and are to receive an OZURDEX
®
intravitreal implant (implant into the vitreous gel that fills the eye), it means
you have RVO that is causing macular edema (swelling). Your doctor will discuss with you the reasons why OZURDEX
®
was selected as well as the benefits and risks of treatment.
What the studies showed
OZURDEX® has been proven effective in large clinical trials and approved
by the FDA. The effectiveness and safety of OZURDEX® intravitreal
implants have been studied in 853 patients who had either branch or central retinal
vein occlusions.
OZURDEX® provided significant vision improvement for many patients vs sham
- 20% (20 of 100) to 30% of patients (30 of 100) who received OZURDEX® gained 3 lines of vision on the eye
chart within 1 to 2 months—compared with 7% (7 of 100) to 12% of patients (12 of
100) who received sham (simulated) injections without drug
- Once vision had improved, the improvement lasted 1 to 3 months
It’s important to remember that each case of retinal vein occlusion is unique. Your own results may vary.
Click the buttons below to learn more about OZURDEX® and how it works:
